Paper Details

  1. Home
  2. Paper Details

LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.

Author: BoersmaE, BogsrudM P, HamkourS, HolvenK B, ImholzB, JohansenA K, KoopalC, LoutersL, RetterstølK, Roeters van LennepJ E, SchreuderM M, SiegersK E, VisserenF L J, van de ReeM A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This cross-sectional study examined LDL-C target attainment and reasons for non-attainment in female and male patients with familial hypercholesterolemia (FH). Only a minority of patients (26.9% of women and 28.9% of men) achieved their LDL-C target. Women were less likely to receive high-intensity statins and ezetimibe, and the most common reasons for non-attainment were insufficient treatment effect and side effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: Despite lipid lowering therapy (LLT), reaching LDL-C targets in patients with familial hypercholesterolemia (FH) remains challenging. Our aim was to determine attainment of LDL-C target levels and reasons for not reaching these in female and male FH patients. METHODS: We perfor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.atherosclerosis.2023.03.022

データ提供：米国国立医学図書館（NLM）

LDL Cholesterol Targets Rarely Achieved in Familial Hypercholesterolemia Patients: A Sex and Gender-Specific Analysis

This study delves into the world of familial hypercholesterolemia (FH), a condition where high cholesterol levels run in families. The researchers are like desert explorers searching for ways to control LDL cholesterol, the ‘bad’ cholesterol, in individuals with FH. They conducted a cross-sectional study to investigate why many FH patients struggle to reach their LDL cholesterol targets, even with medication. The researchers found that women with FH had higher LDL cholesterol levels than men and were less likely to reach their treatment targets. The study also revealed that many patients were not receiving high-intensity statins, which are medications commonly used to lower cholesterol.

A Challenging Journey: Reaching LDL Cholesterol Targets in Familial Hypercholesterolemia

This study highlights the difficulty in managing LDL cholesterol in FH patients, especially women. The authors found that women with FH had higher LDL cholesterol levels than men and were less likely to achieve their treatment targets, suggesting a need for more personalized approaches to managing FH. The study also emphasizes the importance of optimal medication use, particularly the use of high-intensity statins, to effectively manage cholesterol levels in FH patients.

Navigating the Cholesterol Desert: A Call for Personalized Care

This study underscores the importance of personalized treatment approaches for managing FH. The authors highlight the need for more effective communication with patients about the benefits and safety of statins, as well as exploring alternative therapies for individuals who do not achieve their LDL cholesterol targets with statins alone. This research is like finding a hidden oasis in the vast desert of FH management, providing new insights and strategies to improve the health of individuals with this condition.

Dr.Camel's Conclusion

This research emphasizes the importance of personalized treatment for FH patients, particularly women, to effectively manage LDL cholesterol levels. It's like discovering a hidden oasis in the vast desert of cholesterol management, offering new strategies for optimizing treatment and improving outcomes for individuals with FH.

Date :
  1. Date Completed 2023-11-06
  2. Date Revised 2023-11-10
Further Info :

Pubmed ID

37080805

DOI: Digital Object Identifier

10.1016/j.atherosclerosis.2023.03.022

Related Literature

Article Analysis
・Side Effects of ezetimibe
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.